Filgrastim biosimilar - Lupin

Drug Profile

Filgrastim biosimilar - Lupin

Alternative Names: Filgrastim - Lupin; Lupifil

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator Lupin
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant fusion proteins
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Haematopoietic cell growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 19 May 2016 Launched for Neutropenia (Adjunctive treatment, In adults) in India before May 2016 (SC) (Lupin website, July 2016)
  • 15 Mar 2016 Biomarkers information updated
  • 23 Apr 2014 Phase-III clinical trials for Neutropenia (adjunct to chemotherapy in patients with non-myeloid malignancies) in India (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top